SCHEMBL3821053

SCHEMBL3821053

Cc1cc(C)c2oc(Nc3ccc(-c4cn(C5CCC(N6CCN(S(C)(=O)=O)CC6)CC5)c5ncnc(N)c45)cc3F)nc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.74
ERBB2 P04626 5/20 0.74
IGF1R P08069 5/20 0.74
ERBB3 P21860 5/20 0.74
ERBB4 Q15303 5/20 0.74
NEK7 Q8TDX7 10/20 0.49
AURKB Q96GD4 2/20 0.47
AURKA O14965 1/20 0.47
TEK Q02763 1/20 0.47
DYRK3 O43781 1/20 0.46
ROCK2 O75116 1/20 0.46
MAP4K4 O95819 1/20 0.46
ABL1 P00519 1/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
CSF1R P07333 1/20 0.46
LYN P07948 1/20 0.46
RET P07949 1/20 0.46
FGFR1 P11362 1/20 0.46
SRC P12931 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6108420 1.00 EGFR (0.74) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6108958 0.94 EGFR (0.82) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL3818589 0.94 EGFR (0.82) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6109590 0.90 EGFR (0.75) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6109588 0.90 EGFR (0.75) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6108340 0.86 EGFR (0.84) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL3822288 0.86 EGFR (0.84) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6108815 0.85 EGFR (0.69) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6108812 0.85 EGFR (0.69) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6107989 0.85 EGFR (1.00) EGFRERBB2IGF1RERBB3ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730148-A4 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LAB (US) 2009-08-19 EP disclosed
EP-1730148-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2006-12-13 EP disclosed
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 US disclosed
WO-2005074603-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 EGFR 506/4885ERBB2 47/4885IGF1R 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.